Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.0K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.0K
Dementia01:30

Dementia

584
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
584
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

671
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
671
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

243
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
243
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

460
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
460

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dynamic Variation of Secondary Metabolites from <i>Polygonatum cyrtonema</i> Hua Rhizomes During Repeated Steaming-Drying Processes.

Molecules (Basel, Switzerland)·2025
Same author

Nutraceutical Potential of Djulis (<i>Chenopodium formosanum</i>) Hull: Phytochemicals, Antioxidant Activity, and Liver Protection.

Antioxidants (Basel, Switzerland)·2024
Same author

Anti-Inflammatory Effects of Anthocyanin-Enriched Black Soybean Seed Coat (BSSC) Crude Extract on LPS-Induced Acute Liver Injury in Mice.

Antioxidants (Basel, Switzerland)·2024
Same author

Hypoglycemic effects and associated mechanisms of resveratrol and related stilbenes in diet.

Food & function·2024
Same author

Jeremy Morris as a pioneer of behavioural epidemiology, social medicine and public health.

Scandinavian journal of public health·2023
Same author

Health-Promoting Activities and Associated Mechanisms of Polygonati Rhizoma Polysaccharides.

Molecules (Basel, Switzerland)·2023

Related Experiment Video

Updated: Feb 18, 2026

Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

22.4K

Resveratrol, pterostilbene, and dementia.

Klaus W Lange1, Shiming Li2

  • 1Department of Experimental Psychology, University of Regensburg, Germany.

Biofactors (Oxford, England)
|November 24, 2017
PubMed
Summary

Resveratrol and pterostilbene show promise for dementia prevention due to their antioxidant and anti-inflammatory effects. Pterostilbene may be more effective than resveratrol in combating age-related brain changes.

Keywords:
cognitiondementiapolyphenolspterostilbeneresveratrol

More Related Videos

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

12.7K
Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

10.8K

Related Experiment Videos

Last Updated: Feb 18, 2026

Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

22.4K
Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

12.7K
Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

10.8K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Gerontology

Background:

  • Resveratrol and pterostilbene are natural polyphenols with potential neuroprotective properties.
  • These compounds can cross the blood-brain barrier, influencing brain activity.
  • They exhibit antioxidant, anti-inflammatory, and antiamyloid effects in vitro.

Purpose of the Study:

  • To review the evidence on resveratrol and pterostilbene's effects on dementia pathology and cognition.
  • To compare the efficacy of resveratrol and pterostilbene in animal models and human studies.
  • To assess their potential role in preventing and treating dementia syndromes.

Main Methods:

  • Review of existing literature on resveratrol and pterostilbene in dementia models.
  • Analysis of in vitro, in vivo (animal), and human clinical trial data.
  • Comparison of the chemical properties influencing bioavailability and efficacy.

Main Results:

  • Both compounds show protection against Alzheimer's disease and vascular dementia in cellular and animal models.
  • Pterostilbene appears more effective than resveratrol against age-related brain changes due to higher lipophilicity.
  • Current human trials with resveratrol show no significant neuroprotective or therapeutic effects.

Conclusions:

  • Resveratrol and pterostilbene demonstrate neuroprotective potential for dementia prevention and treatment.
  • Further long-term clinical trials with high-bioavailability formulations are needed.
  • Pterostilbene's enhanced efficacy warrants further investigation for cognitive health.